Cinrebafusp Biosimilar Fusion Protein (HER2) for Research

Cat No.: GMP-Bios-INN-1134

Anti-ERBB2/CD340/HER2 therapeutic antibody (Pre-made Cinrebafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cinrebafusp (development code PRS-343) is a bispecific antibody fusion protein targeting HER2 and 4-1BB (TNFRSF9). It is developed by Pieris Pharmaceuticals with Eli Lilly and Seagen for gastric cancer and other solid tumors. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1134-1mg 1mg 3090
GMP-Bios-INN-1134-10mg 10mg
GMP-Bios-INN-1134-100mg 100mg
GMP-Bios-INN-1134-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Cinrebafusp biosimilar, Fusion Protein targeting ERBB2/CD340/HER2: Recombinant therapeutic protein targeting HER2/ERBB2/CD340/Receptor tyrosine-protein kinase erbB-2
INN Name Cinrebafusp
Target ERBB2/CD340/HER2
Format Fusion Protein
Derivation na
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure 6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA
99% SI Structure 1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL
95-98% SI Structure 5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL
Year Proposed 2019
Year Recommended 2020
Companies Eli Lilly and Company;Pieris Pharmaceuticals;Seagen
Conditions Approved na
Conditions Active Gastic cancer;Solid tumours
Conditions Discontinued na
Production na
Development Tech na